Diligence memo · auto-generated · as of July 3, 2026
Genelink Inc
Genelink Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Genelink Inc operates in Biotechnology, based in ORLANDO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Genelink Inc has raised $2.7M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.6M on 2012-06-20.
Most recent recorded round closed around 2012-06-20.
Valuation (modeled)modeled
Provath models Genelink Inc at approximately $70M (range $1.1M–$549M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.81× the median modeled value of Seed Biotechnology companies in 2010–2012 (151 peers) — value vs value, same stage and era. Within the normal band (81% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 14.0 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 7.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 32% of Biotechnology peers (4293 compared).
Modeled value ranks above 52% of those peers.
Closest niche peers: Denali Medical II, Inc., Signum Biosciences, Inc., Health Elements, LLC, Nkt Therapeutics Inc, Surface Logix Inc.
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.